← Leaderboards
Warren D Shlomchik
Yale University
$17,313,205
Attributed
$18,553,538
Total exposure
12
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,671,291 · 11
FDA$882,247 · 1
By mechanism
R01$15,339,286 · 7
P01$1,783,648 · 1
P30$962,321 · 2
K08$368,283 · 1
R41$100,000 · 1
Top collaborators
- Mark J Shlomchik4 shared
- Sawa Ito1 shared
Most similar at Yale University
Same institution · by research overlap
- Nancy Berliner$13,688,063
- Ira S Mellman$8,006,553
- Markus Mãschen$33,184,326
- Ian Nicholas Crispe$19,287,066
- Archibald S Perkins$6,074,658
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsMediatingImmuneAllogenicT-LymphocyteLeukemiaStem Cell TransplantResponseHematologic NeoplasmsGenesTissuesPathogenSignal TransductionCell PhysiologyPathway InteractionsPersonsGraft-Vs-Host DiseaseAllograftingPropertyReconstitutionStem CellsAlloantigenGraft Vs Leukemia EffectSickle Cell Anemia
Grant awards (54)
Graft-versus-Host Disease: Local Maintenance by Tissue Resident Progenitor T cells$747,995
R01 · FY2025 · HL · contact PI
Phase 2 Study of Interferon-Gamma and Donor Lymphocyte Infusion for the Treatment of Relapsed Myeloid Malignancies after Allogeneic Stem Cell Transplantation$882,247
R01 · FY2024 · FD
Mechanisms whereby IFN-gamma sensitizes AML to the graft-vs-leukemia effect$539,158
R01 · FY2024 · HL · contact PI
Mechanisms whereby IFN-gamma sensitizes AML to the graft-vs-leukemia effect$604,596
R01 · FY2023 · HL · contact PI
Mechanisms whereby IFN-gamma sensitizes AML to the graft-vs-leukemia effect$596,963
R01 · FY2022 · HL · contact PI
Graft-versus-Host Disease: Local Maintenance in Target Tissues by Tissue Resident Memory-Type Cells.$632,628
R01 · FY2021 · HL · contact PI
Mechanisms whereby IFN-gamma sensitizes AML to the graft-vs-leukemia effect$585,063
R01 · FY2021 · HL · contact PI
Graft-versus-Host Disease: Local Maintenance in Target Tissues by Tissue Resident Memory-Type Cells.$651,301
R01 · FY2020 · HL · contact PI
Graft-versus-Host Disease: Local Maintenance in Target Tissues by Tissue Resident Memory-Type Cells.$655,553
R01 · FY2019 · HL · contact PI
Graft-versus-Host Disease: Local Maintenance in Target Tissues by Tissue Resident Memory-Type Cells.$568,001
R01 · FY2018 · HL · contact PI
Research Core (Amnis ImageStreamX Core)$167,488
P30 · FY2017 · AR · contact PI
GVL Resistance: Immune selection, T cell ignorance and T cell exhaustion$385,000
R01 · FY2016 · HL · contact PI
Research Core (Amnis ImageStreamX Core)$155,574
P30 · FY2016 · AR · contact PI
GVL Resistance: Immune selection, T cell ignorance and T cell exhaustion$379,225
R01 · FY2015 · HL · contact PI
Role of Tissue Antigen Presenting Cells in GVHD$379,225
R01 · FY2015 · HL · contact PI
Transfusion of Donor Effector Memory T Cells for GVL and Immune Reconstitution$379,225
R01 · FY2015 · HL · contact PI
Research Core (Amnis ImageStreamX Core)$156,112
P30 · FY2015 · AR · contact PI
Role of Tissue Antigen Presenting Cells in GVHD$407,925
R01 · FY2014 · HL · contact PI
GVL Resistance: Immune selection, T cell ignorance and T cell exhaustion$407,925
R01 · FY2014 · HL · contact PI
Transfusion of Donor Effector Memory T Cells for GVL and Immune Reconstitution$407,925
R01 · FY2014 · HL · contact PI
Research Core (Amnis ImageStreamX Core)$157,237
P30 · FY2014 · AR · contact PI
Role of Tissue Antigen Presenting Cells in GVHD$396,270
R01 · FY2013 · HL · contact PI
Transfusion of Donor Effector Memory T Cells for GVL and Immune Reconstitution$396,270
R01 · FY2013 · HL · contact PI
GVL Resistance: Immune selection, T cell ignorance and T cell exhaustion$396,178
R01 · FY2013 · HL · contact PI
Leukemia Stem Cells: Essential Targets for GVL and Mediators of GVL-Resistance$262,329
R01 · FY2013 · CA · contact PI
Research Core (Amnis ImageStreamX Core)$154,001
P30 · FY2013 · AR · contact PI
Role of Tissue Antigen Presenting Cells in GVHD$415,000
R01 · FY2012 · HL · contact PI
Transfusion of Donor Effector Memory T Cells for GVL and Immune Reconstitution$415,000
R01 · FY2012 · HL
Leukemia Stem Cells: Essential Targets for GVL and Mediators of GVL-Resistance$279,073
R01 · FY2012 · CA · contact PI
Research Core (Amnis ImageStreamX Core)$99,650
P30 · FY2012 · AR · contact PI
Role of Tissue Antigen Presenting Cells in GVHD$413,750
R01 · FY2011 · HL · contact PI
Leukemia Stem Cells: Essential Targets for GVL and Mediators of GVL-Resistance$279,073
R01 · FY2011 · CA · contact PI
Dendritic Cell Subsets and Paths of Maturation in GVHD$489,806
P01 · FY2010 · AI · contact PI
Leukemia Stem Cells: Essential Targets for GVL and Mediators of GVL-Resistance$287,704
R01 · FY2010 · CA · contact PI
Dendritic Cell Subsets and Paths of Maturation in Graft-vs.-Host Disease (GVHD)$165,500
R01 · FY2010 · HL · contact PI
Dendritic Cell Subsets and Paths of Maturation in GVHD$346,142
P01 · FY2009 · AI · contact PI
Leukemia Stem Cells: Essential Targets for GVL and Mediators of GVL-Resistance$287,704
R01 · FY2009 · CA · contact PI
Dendritic Cell Subsets and Paths of Maturation in Graft-vs.-Host Disease (GVHD)$165,500
R01 · FY2009 · HL · contact PI
Dendritic Cell Subsets and Paths of Maturation in GVHD$322,160
P01 · FY2008 · AI · contact PI
Dendritic Cell Subsets and Paths of Maturation in Graft-vs.-Host Disease (GVHD)$165,500
R01 · FY2008 · HL · contact PI
Dendritic Cell Subsets and Paths of Maturation in GVHD$322,619
P01 · FY2007 · AI · contact PI
Graft Versus Leukemia Against Murine Chronic Phase & Blast Crisis CML$275,949
R01 · FY2007 · CA · contact PI
Dendritic Cell Subsets and Paths of Maturation in Graft-vs.-Host Disease (GVHD)$165,000
R01 · FY2007 · HL · contact PI
Dendritic Cell Subsets and Paths of Maturation in GVHD$302,921
P01 · FY2006 · AI · contact PI
GVL Against Murine Chronic Phase and Blast Crisis CML$284,191
R01 · FY2006 · CA · contact PI
Dendritic Cell Subsets and Paths of Maturation in GVHD$206,250
R01 · FY2006 · HL · contact PI
GVL Against Murine Chronic Phase and Blast Crisis CML$291,030
R01 · FY2005 · CA
Novel Immunotoxins for Depletion of Dendritic Cells$100,000
R41 · FY2005 · HL
GVL Against Murine Chronic Phase and Blast Crisis CML$291,030
R01 · FY2004 · CA
GVL Against Murine Chronic Phase and Blast Crisis CML$291,030
R01 · FY2003 · CA
ALLOIMMUNITY TO CML IN A NOVEL MURINE MODEL$122,761
K08 · FY2002 · HL
ALLOIMMUNITY TO CML IN A NOVEL MURINE MODEL$122,761
K08 · FY2001 · HL
ALLOIMMUNITY TO CML IN A NOVEL MURINE MODEL$122,761
K08 · FY2000 · HL
Pathogenic mechanisms of GVD in murine model$72,259
P30 · FY2000 · AR